UPDATE - Canaccord Genuity Initiates Coverage on PhotoMedex (PHMD) with a Buy; Near-term Growth Consumer Driven
Tweet
Share
E-mailGet Alerts PHMD Hot Sheet
Price: $1.07 --0%
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - Canaccord Genuity initiates coverage on PhotoMedex (NASDAQ: PHMD) with a Buy. PT $22.00.
Analyst, William J. Plovanic, said, "We believe the merger of PhotoMedex and Radiancy creates leverage opportunities both on the top and bottom lines with results expected starting in the H2/12. Revenue synergies are expected from cross-selling of PhotoMedex products into the consumer channel and utilizing Radiancy’s existing DTC expertise. In addition cost synergies are expected as infrastructure is maximized to support the combined businesses."
Plovanic sees near-term growth being supported by consumer product segments.
To see more ratings on PHMD, Click Here
Analyst, William J. Plovanic, said, "We believe the merger of PhotoMedex and Radiancy creates leverage opportunities both on the top and bottom lines with results expected starting in the H2/12. Revenue synergies are expected from cross-selling of PhotoMedex products into the consumer channel and utilizing Radiancy’s existing DTC expertise. In addition cost synergies are expected as infrastructure is maximized to support the combined businesses."
Plovanic sees near-term growth being supported by consumer product segments.
To see more ratings on PHMD, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
